SEOUL: Samsung BioLogics Co Ltd, a contract manufacturer of biotech drugs for global pharmaceutical firms, said its initial public offering is expected to raise as much as US$2bil in what is set to be South Korea's third-largest IPO.
The listing is aimed at helping fund an ambitious expansion in production capacity to make it the world's largest contract manufacturer.
